Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

Sanofi

Status and phase: Completed; Phase 1

Conditions: Type 1 Diabetes Mellitus

Treatments: Drug: insulin lispro; Drug: SAR342434

Study type: Interventional

Funder types: Industry

Identifiers

NCT02603510

U1111-1170-3739 (Other Identifier)

PDY13502

Details and patient eligibility

About

Primary Objective:

• Assess the safety of SAR342434 and Humalog when used in external pumps.

Secondary Objectives:

• Intervals for infusion set changes.
• Incidence of insulin pump alarms for infusion set occlusion.
• Patient observation of infusion set occlusion.
• Adverse events including bruising at the infusion site and injection site reactions.

Full description

The study duration for each patient will be approximately 10 weeks.

Enrollment: 27 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria :

• Male and female subjects above the age of 18.
• Patients with type 1 diabetes mellitus for at least 1 year prior to the screening visit.
• At least 1 year of insulin treatment with at least 6 months of continuous subcutaneous insulin infusion (CSII) treatment with an external insulin pump.
• Signed written informed consent.

Exclusion criteria:

• HbA1c ≥8.5% at screening.
• Diabetes other than type 1 diabetes mellitus.
• History of abscess at the infusion site within 3 months prior to the screening visit (Visit 1).
• Use of oral glucose-lowering agents or any injectable glucose-lowering agents other than insulin during the 3 months before screening.
• Hospitalization for diabetic ketoacidosis (DKA) in the last 6 months before screening visit.
• Hypoglycemic unawareness as judged by the Investigator in the last 6 months before the screening visit.
• History of severe hypoglycemia requiring treatment by emergency room admission or hospitalization in the last 6 months before screening visit.
• Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study.
• Known history of drug or alcohol abuse within 6 months prior to the time of screening.
• Use of investigational drug(s) within 3 months or 5 half-lives, whichever is longer, prior to the screening visit.
• Patients who had previously received SAR342434 in any other clinical trial.
• Pregnancy and lactation: Women of child bearing potential (WOCPB) (premenopausal, not surgically sterile for at least 3 months prior to the time of screening) not using highly effective (ie, with low failure rate <1% per year) method(s) of birth control throughout the study and/or unwilling to be tested for pregnancy.
• Any contraindication to the use of Humalog as defined in the national product labels; history of hypersensitivity to Humalog or to any of the excipients.
• Patients is an employee or relative of an employee of the Sponsor.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

27 participants in 2 patient groups

SAR342434/Humalog

Experimental group

Description:

SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.

Treatment:

Drug: SAR342434

Drug: insulin lispro

Humalog/SAR342434

Experimental group

Description:

Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.

Treatment:

Drug: SAR342434

Drug: insulin lispro